McKesson Corp.
McKesson Corporation (MCK)
Overview
McKesson Corporation is one of the largest healthcare companies in the United States and a dominant force in pharmaceutical distribution, with roots tracing back to 1833. Headquartered in Irving, Texas (having relocated from San Francisco in 2019), McKesson operates in the Healthcare sector, specifically the medical distribution industry. It is consistently ranked among the largest companies in the U.S. by revenue — historically inside the top ten of the Fortune 500 — reflecting the sheer volume of pharmaceutical products that flow through its distribution network. McKesson's revenue has grown rapidly in recent years, reaching roughly $359 billion for fiscal 2025 (with trailing-twelve-month revenue over $400 billion), and net income of approximately $4.6 billion. Headcount has shifted recently: the company reported over 80,000 employees prior to 2025 but roughly 43,000 following the spin-off of its medical-surgical distribution business.
What They Do & How They Make Money
McKesson's core business is pharmaceutical distribution: it buys prescription drugs — branded, generic, specialty, biosimilar, and over-the-counter — in enormous volume directly from drug manufacturers, and then distributes them efficiently to retail pharmacies (including chain drugstores, independent pharmacies, and mass merchandisers), hospitals, health systems, long-term care facilities, and clinics across North America and parts of Europe. McKesson is estimated to handle roughly a third of all pharmaceuticals consumed in North America, making it a critical, largely invisible link in the healthcare supply chain. Because pharmaceutical distribution is a high-volume, low-margin business, McKesson makes money primarily on razor-thin per-unit distribution margins multiplied across an enormous volume of transactions, supplemented by fees for value-added services (inventory management, data analytics, generic-sourcing programs, and specialty pharmacy logistics). Beyond core distribution, McKesson has built higher-margin businesses around oncology practice support (helping community oncology practices with drug procurement, technology, and practice management), prescription technology and data solutions (software and analytics that connect payers, pharmacies, and providers), and — until its recent spin-off — medical-surgical supply distribution to healthcare providers. McKesson also owns and franchises pharmacy networks such as Health Mart, giving independent pharmacies group purchasing power and branding support in exchange for fees.
Business Segments
McKesson's reporting segments (reflecting a 2024–2025 reorganization, including the announced spin-off of its Medical-Surgical Solutions business) include:
- U.S. Pharmaceutical (North American Pharmaceutical) — The core business: distribution of branded, generic, specialty, and biosimilar drugs and over-the-counter products to retail and institutional pharmacy customers across the U.S. and Canada. This segment generates the overwhelming majority of McKesson's total revenue, though at very low margins typical of pharmaceutical distribution.
- Oncology & Multispecialty (formerly U.S. Specialty Health / Prescription Technology Solutions territory) — Services and drug distribution for community oncology and other specialty physician practices, including group purchasing, technology platforms, and data/analytics offerings that help specialty practices manage complex drug regimens and payer relationships.
- Prescription Technology Solutions — Software, data, and technology services that connect pharmacies, payers, and life-sciences companies, supporting prescription access, adherence, and reimbursement workflows.
- Medical-Surgical Solutions — Distribution of medical-surgical supplies and equipment to physician offices, surgery centers, long-term care, and other alternate-site providers. McKesson announced plans in 2025 to spin this business off as an independent, separately traded company, reducing McKesson's consolidated headcount and narrowing its focus toward pharmaceutical distribution, oncology, and technology-driven healthcare services.
McKesson does not typically break out granular segment-level revenue and profit figures in high-level summaries, but the Pharmaceutical distribution segment represents the large majority of both revenue and total volume, while segments like Oncology and Prescription Technology Solutions contribute disproportionately more to operating profit relative to their smaller revenue share, given their higher-margin, services-oriented nature.
Competitors
- Pharmaceutical distribution: Cencora (formerly AmerisourceBergen) and Cardinal Health are McKesson's two primary direct competitors; together the three companies form an oligopoly that handles the vast majority of U.S. pharmaceutical distribution volume.
- Medical-surgical supply distribution: Owens & Minor, Henry Schein, and Cardinal Health's medical segment compete in medical-surgical product distribution.
- Specialty/oncology services: Cencora's oncology and specialty distribution units, along with various independent group purchasing organizations (GPOs) and specialty pharmacy providers, compete for oncology practice relationships.
- Pharmacy technology/data services: Companies like Cencora's technology platforms, health-IT vendors, and pharmacy benefit managers' technology arms compete in prescription technology and adherence solutions.
- Vertically integrated threats: Large payers and PBMs with in-house distribution or specialty pharmacy capabilities (e.g., CVS Health/Caremark, Cigna's Evernorth/Express Scripts, UnitedHealth's Optum) represent a longer-term competitive and disintermediation risk, as they can bypass traditional wholesalers for parts of the supply chain.
Competitive Position
McKesson's competitive position rests on scale and entrenched infrastructure that would be extraordinarily difficult and capital-intensive to replicate. Along with Cencora and Cardinal Health, McKesson operates in a highly consolidated, oligopolistic distribution market with enormous fixed-cost logistics networks (warehouses, delivery fleets, inventory systems) that create real barriers to entry — few companies could realistically build a competing nationwide pharmaceutical distribution network from scratch. This scale also gives McKesson negotiating leverage with drug manufacturers on pricing and rebates, and with large pharmacy chains and health systems on distribution contracts, reinforcing a scale-based cost advantage. The company's ongoing pivot toward higher-margin, technology- and services-driven businesses — oncology practice support, prescription technology, and data/analytics — is a deliberate strategy to improve blended margins beyond the thin economics of pure drug distribution, and the planned Medical-Surgical Solutions spin-off reflects a broader move to sharpen focus on pharmaceutical distribution and specialty/oncology growth.
Key risks and threats include: continued margin pressure from generic-drug deflation and payer/PBM pricing pressure; regulatory and legal risk tied to the opioid crisis — McKesson was one of several major distributors that agreed to a roughly $26 billion multi-state settlement (finalized in 2022) over opioid distribution practices, and similar litigation or regulatory scrutiny could recur; disintermediation risk from large vertically integrated healthcare and payer conglomerates (CVS/Caremark, UnitedHealth/Optum, Cigna/Evernorth) that increasingly control pharmacy benefit management, specialty pharmacy, and even direct drug sourcing, potentially bypassing traditional wholesalers; cybersecurity risk given McKesson's centrality to the pharmaceutical supply chain and its growing data/technology businesses; and execution risk around the Medical-Surgical Solutions spin-off, which must be completed without disrupting existing customer relationships or costing McKesson valuable diversification. McKesson's ability to keep growing profitably will likely depend on successfully shifting its business mix toward higher-margin specialty, oncology, and technology services while defending its core distribution scale advantage against consolidation among its direct competitors and encroachment from integrated payer-PBM giants.